Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04438382 | Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis | terminated | Phase 2 | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05052255 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 66 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT03585465 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors(Metro-PD1) | terminated | Phase 1 / Phase 2 | 63 | Centre Oscar LambretOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 429 | GenmabINDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Incyte CorporationINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | terminated | Phase 1 / Phase 2 | 21 | GenmabINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | terminated | Phase 1 / Phase 2 | 3 | Tianhong LiOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05307874 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors(EVICTION-2) | terminated | Phase 1 / Phase 2 | 56 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 3 | Jul 30, 2026 | clinicaltrials |
| NCT05826600 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | terminated | Phase 1 / Phase 2 | 68 | iOmx Therapeutics AGINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | GenmabINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05525247 | A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | terminated | Phase 1 / Phase 2 | 27 | SelecxineINDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT05159388 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | Servier Bio-Innovation LLCINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04168528 | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | terminated | Phase 1 / Phase 2 | 13 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05729399 | Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | terminated | Phase 1 / Phase 2 | 110 | Tango Therapeutics, Inc.INDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 188 | Ascendis Pharma Oncology Division A/SINDUSTRY | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05262530 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | terminated | Phase 1 / Phase 2 | 73 | BioNTech SEINDUSTRY | 4 | Apr 8, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05023655 | Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | terminated | Phase 2 | 20 | Prisma Health-UpstateOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06005974 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | terminated | Phase 2 | 18 | Recursion Pharmaceuticals Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT04617054 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | terminated | Phase 2 | 14 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors | terminated | Phase 2 | 3 | CytomX TherapeuticsINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT04276376 | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors(ARIANES) | terminated | Phase 2 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | terminated | Phase 2 | 36 | Artios Pharma LtdINDUSTRY | 3 | Nov 6, 2025 | clinicaltrials |
| NCT04972110 | Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors(ATTACC) | terminated | Phase 1 / Phase 2 | 156 | Repare TherapeuticsINDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 137 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | terminated | Phase 1 / Phase 2 | 70 | Incyte CorporationINDUSTRY | 3 | Oct 21, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05221320 | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | terminated | Phase 2 | 47 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05821777 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Centessa Pharmaceuticals (UK) LimitedINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT06175221 | Autologous TLPO Vaccine Basket | terminated | Phase 2 | 63 | Elios Therapeutics, LLCINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06226766 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | terminated | Phase 1 / Phase 2 | 11 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05208177 | A Study of SHR-1802 in Patients With Advanced Solid Tumor | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials